Products with Insulin-stimulated action bioactivity
| Cat.No. | Product Name |
|---|---|
| BCN2718 | Dehydrotrametenolic acid |
| Dehydrotrametenolic acid is a promising candidate for a new type of insulin-sensitizing drug; it can be a potential anticancer agent against H-ras transformed tumor. | |
| BCN2733 | Bergamotine |
| 1. Bergamotine can significantly reduce blood glucose and increase glucose tolerance and insulin sensitivity in KK-Aydiabetic mice. | |
| BCN4222 | Moronic acid |
| 1. Moronic acid shows oral therapeutic efficacy in HSV-infected mice and possessed novel anti-HSV activity. 2. Moronic acid is a new structural lead for anti-EBV drug development, can substantially reduce the numbers of EBV particles produced by the cells after lytic induction. 3. Moronic acids inhibits the capacity of Rta to activate a promoter that contains an Rta-response element, indicating that Moronic acid interferes with the function of Rta. 4. Moronic acid shows significant anti-HIV activity (EC(50) 186) and was modified to develop more potent anti-AIDS agents. 5.Morolic and moronic acids have shown sustained antidiabetic and antihyperglycemic action possibly mediated by an insulin sensitization with consequent changes of glucose, cholesterol and triglycerides, in part mediated by inhibition of 11β-HSD 1 as indicated by in vitro. | |
| BCN4538 | Kazinol B |
| 1. Kazinol B inhibits the NO synthesis with an IC(50) of 21.6 microM. 2. Kazinol B can stimulate respiratory burst, is probably mediated by the synergism of PKC activation and [Ca2+]i elevation in rat neutrophils. 3. Kazinol B stimulates Ca(2+) release from internal Ca(2+) store, probably through the sphingosine 1-phosphate and IP(3) signaling, and activates external Ca(2+) influx mainly through a non-store-operated Ca(2+) entry (non-SOCE) pathway. 4. Kazinol B inhibits SOCE, is probably attributable to a break in the Ca(2+) driven force of mitochondria. 5. Kazinol B improves insulin sensitivity via Akt and AMPK activation in 3T3-L1 adipocytes, it might be a therapeutic candidate for diabetes mellitus. | |
| BCN4872 | Bavachin |
| Bavachin is a phytoestrogen that activates the estrogen receptors ERα and ERβ with EC50s of 320 and 680 nM, respectively. It is a cholesterol acyltransferase inhibitor, may have therapeutic potential for type 2 diabetes by activating insulin signaling pathways. Bavachin can stimulate the genetic expression of VEGF in PB,and directly help the fracture healing, and potentially protect cartilage from inflammation-mediated damage in joints of osteoarthritis patients through decreasing IL-1β-induced activation of IKK-IκBα-NF-κB signaling pathway. Bavachin has suppressive effects against pigmentation by melanin in the skin. | |
